Latest news with #Chemkart
&w=3840&q=100)
Business Standard
6 days ago
- Business
- Business Standard
Chemkart India shares make flat D-Street debut, list at ₹250 on BSE
Chemkart India IPO listing today: Shares of food and health ingredients company Chemkart India made a positive debut on the BSE SME platform today, July 14, 2025, following the completion of its initial public offering (IPO). The stock listed at ₹250 per share, reflecting a premium of only ₹2 or 0.8 per cent over the issue price of ₹248. Chemkart India IPO listing was in-line with the grey market estimates. Ahead of the listing, the unlisted shares of Chemkart were trading at around ₹251, indicating a grey market premium (GMP) of ₹3 or around 1.2 per cent over the issue price, according to sources tracking unofficial market activity. Chemkart India IPO details Chemkart India IPO comprises a fresh issue of 2.6 million equity shares aggregating to ₹64.48 crore and an offer for sale (OFS) up to 0.63 million equity shares worth ₹15.6 crore. The public offering was available for subscription from Monday, July 7, to Wednesday, July 9, at a price band of ₹236 to ₹248 per share and a lot size of 600 shares. The public issue received a lacklustre demand from investors, getting oversubscribed by only 5.9 times by the end of the subscription period, showed the BSE data. The portion reserved for qualified institutional buyers (QIBs) was booked 13.69 times, followed by non-institutional investors quota at 5.64 times and retail investors portion was booked 1.63 times. Chemkart India will not receive any proceeds from the OFS. According to the RHP, the company proposes to utilise the proceeds from the fresh offering for the setting up of the manufacturing facility through investment in the wholly owned subsidiary, Easy Raw Materials, and to repay debt. The remaining funds will be used for general corporate purposes. About Chemkart India Incorporated in 2020, Mumbai-based Chemkart India provides nutritional, health and sports supplement products. It offers products across mainly seven product categories, including Amino Acids, Health Supplement, Herbal Extract, Nucleotide, Protein, Sports Nutrition, and Vitamin. The company operates a facility for grinding, blending, and packaging services in Bhiwandi, Mumbai. Its product portfolio includes amino acid, health supplements, herbal extracts, nucleotide, protien, sports nutrition, and vitamins.
Economic Times
07-07-2025
- Business
- Economic Times
Chemkart India IPO: Check GMP, price band and other details
Mumbai's Chemkart India, a B2B food and health ingredient distributor, is launching its IPO today. The company aims to raise Rs 80.08 crore. The IPO includes a fresh issue and an offer for sale. The issue closes on July 9, with BSE SME listing expected on July 14. Proceeds will fund expansion and debt repayment. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Chemkart India, a Mumbai-based B2B distributor of food and health ingredients, will open its IPO today, aiming to raise Rs 80.08 crore through a mix of fresh issue and offer for sale. The three-day issue will close on July 9, with shares expected to list on the BSE SME platform on July IPO comprises a fresh issue of 26 lakh shares aggregating up to Rs 64.48 crore and an offer for sale (OFS) of 6.29 lakh shares worth Rs 15.60 price band is fixed at Rs 236–248 per share, with a lot size of 600 shares. Ahead of the issue opening, the GMP is Rs 0 in the unlisted Horizon Capital Advisors is the lead manager to the issue, with Bigshare Services as registrar. Alacrity Securities is the market in 2015, Chemkart operates in the health and food ingredients segment, supplying amino acids, herbal extracts, vitamins, proteins, and sports nutrition components to supplement company also offers in-house services like grinding, blending, and packaging at its 28,000 sq. ft. facility in Bhiwandi, enhancing its control over quality and IPO proceeds will fund capital expenditure through investment in its wholly owned subsidiary, Easy Raw Materials, repay existing borrowings, and meet general corporate of FY25, Chemkart reported a 55% jump in revenue to Rs 205.46 crore and a 67% rise in profit after tax at Rs 24.26 crore. Its return on equity stands at 59%, with a healthy EBITDA margin of 16.12%.: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
Time of India
07-07-2025
- Business
- Time of India
Chemkart India IPO: Check GMP, price band and other details
Live Events (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel Chemkart India, a Mumbai-based B2B distributor of food and health ingredients, will open its IPO today, aiming to raise Rs 80.08 crore through a mix of fresh issue and offer for sale. The three-day issue will close on July 9, with shares expected to list on the BSE SME platform on July IPO comprises a fresh issue of 26 lakh shares aggregating up to Rs 64.48 crore and an offer for sale (OFS) of 6.29 lakh shares worth Rs 15.60 price band is fixed at Rs 236–248 per share, with a lot size of 600 shares. Ahead of the issue opening, the GMP is Rs 0 in the unlisted Horizon Capital Advisors is the lead manager to the issue, with Bigshare Services as registrar. Alacrity Securities is the market in 2015, Chemkart operates in the health and food ingredients segment, supplying amino acids, herbal extracts, vitamins, proteins, and sports nutrition components to supplement company also offers in-house services like grinding, blending, and packaging at its 28,000 sq. ft. facility in Bhiwandi, enhancing its control over quality and IPO proceeds will fund capital expenditure through investment in its wholly owned subsidiary, Easy Raw Materials, repay existing borrowings, and meet general corporate of FY25, Chemkart reported a 55% jump in revenue to Rs 205.46 crore and a 67% rise in profit after tax at Rs 24.26 crore. Its return on equity stands at 59%, with a healthy EBITDA margin of 16.12%.: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
